[
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=380308b1b5bc6d183c3f10e1908616d58fe98239cbd0e5986d29648458544741",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739291760,
      "headline": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
      "id": 132683287,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=380308b1b5bc6d183c3f10e1908616d58fe98239cbd0e5986d29648458544741"
    }
  },
  {
    "ts": null,
    "headline": "Steady M&A Deals To Begin 2025, Disappointing IPOs So Far",
    "summary": "A few notable health care deals along with M&A in the AI-adjacent and reshoring themes occurred in January. Read more here.",
    "url": "https://finnhub.io/api/news?id=672b6866755d06c6e531c019654992d06ff098e491e3acc23ca6d5923d328a83",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739238000,
      "headline": "Steady M&A Deals To Begin 2025, Disappointing IPOs So Far",
      "id": 132656392,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912015742/image_912015742.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "A few notable health care deals along with M&A in the AI-adjacent and reshoring themes occurred in January. Read more here.",
      "url": "https://finnhub.io/api/news?id=672b6866755d06c6e531c019654992d06ff098e491e3acc23ca6d5923d328a83"
    }
  },
  {
    "ts": null,
    "headline": "Sangamo Therapeutics: Challenging Road Ahead After Pfizer Exit",
    "summary": "Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO stock is a Sell.",
    "url": "https://finnhub.io/api/news?id=a1367328eda9ea0b5d9e0af653be5e02bc210cb27aa671ee6e237ec5fa44436c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739232818,
      "headline": "Sangamo Therapeutics: Challenging Road Ahead After Pfizer Exit",
      "id": 132656100,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/479454756/image_479454756.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO stock is a Sell.",
      "url": "https://finnhub.io/api/news?id=a1367328eda9ea0b5d9e0af653be5e02bc210cb27aa671ee6e237ec5fa44436c"
    }
  }
]